Search results
Results from the WOW.Com Content Network
A glass of red wine. The health effects of wine are mainly determined by its active ingredient – alcohol. [1] [2] Preliminary studies found that drinking small quantities of wine (up to one standard drink per day for women and one to two drinks per day for men), particularly of red wine, may be associated with a decreased risk of cardiovascular diseases, cognitive decline, stroke, diabetes ...
For patients with acid reflux, he recommends avoiding or minimizing spicy foods, caffeine, alcohol and chocolates. “But with PPI (proton pump inhibitors) and other antacids, [these] patients ...
Gastritis caused by H. pylori infection is termed Helicobacter pylori induced gastritis, and listed as a disease in ICD11. [6] [7] More than 80% of individuals infected with the bacterium are asymptomatic and it has been postulated that it may play an important role in the natural stomach ecology. [17]
Gastroesophageal reflux disease (GERD) or gastro-oesophageal reflux disease (GORD) is a chronic upper gastrointestinal disease in which stomach content persistently and regularly flows up into the esophagus, resulting in symptoms and/or complications. [6][7][10] Symptoms include dental corrosion, dysphagia, heartburn, odynophagia, regurgitation ...
It is, however, important to consider the potential health risks when you do choose to drink it. “While moderate consumption of one glass of wine, 2-3 times per week, is unlikely to cause harm ...
Taking in the carbonation leads to gas in the upper digestive system. This excess gas could lead to bloating in the stomach and belching (burping). Beer is carbonated, so it can lead to excess gas ...
Atrophic gastritis is a process of chronic inflammation of the gastric mucosa of the stomach, leading to a loss of gastric glandular cells and their eventual replacement by intestinal and fibrous tissues. As a result, the stomach's secretion of essential substances such as hydrochloric acid, pepsin, and intrinsic factor is impaired, leading to ...
Patients with non-localized (i.e. systemic Ann Arbor stage III and IV) disease who are free of symptoms have been treated with watchful waiting or, if symptomatic, with the immunotherapy drug, rituximab, (given for 4 weeks) combined with the chemotherapy drug, chlorambucil, for 6–12 months; 58% of these patients attain a 58% progression-free ...